U.S. markets open in 7 hours 45 minutes

BioLineRx Ltd. (BLRX.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
60.00+0.70 (+1.18%)
At close: 5:24PM IDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close59.30
Bid59.90 x 255900
Ask60.00 x 42900
Day's Range59.40 - 61.70
52 Week Range33.50 - 136.00
Avg. Volume717,556
Market Cap42.569B
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateNov 22, 2021 - Nov 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BLRX.TA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Globa

    • Insider Monkey

      11 Best Stocks for Long Term Growth

      In this article, we discuss the 11 best stocks for long-term growth. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks for Long Term Growth. As the economy recovers post COVID-19, many investors see the surge in consumer spending and the expansion of the digital economy […]

    • PR Newswire

      BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.